Fortnightly Review: The therapeutic use of bisphosphonates
BMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6956.711 (Published 17 September 1994) Cite this as: BMJ 1994;309:711
- J E Compston
- Department of Medicine, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge CB2 2QQ.
- Accepted 24 March 1994
Bisphosphonates are synthetic analogues of pyrophosphate, a naturally occurring substance which inhibits the mineralisation of bone. The therapeutic potential of these compounds, however, lies in their ability to inhibit bone resorption, and over the past two decades several bisphosphonates have been developed and evaluated in hyperresorptive states, particularly Paget's disease, hypercalcaemia of malignancy, and osteoporosis.1
Structure of bisphosphonates
Bisphosphonates are characterised by two carbon-phosphorus bonds, the carbon atom replacing the oxygen in the P-O-P (phosphorus-oxygen- phosphorus) bond of pyrophosphate (fig 1) and the P-C-P (phosphorus carbon-phosphorus) bond conferring resistance to chemical and enzymatic hydrolysis. Different substitutions on the carbon atom have created several different bisphosphonates, each with its own individual pharmacological properties. The first bisphosphonate to be used therapeutically was etidronate, and subsequently many others have been developed. In order of increasing potency of antiresorptive activity the main bisphosphonates are etidronate, tiludronate, clodronate, pamidronate, alendronate, and risendronate.
Chemical structure of pyrophosphate and three bisphosphonates
Effects of bisphosphonate on bone Bone resorption
The antiresorptive potency of the different compounds of bisphosphonate varies considerably. The antiresorptive effect is believed to be cell mediated but its mechanism has not been clearly established. Effects on osteoclast differentiation, recruitment, and activity have all been reported, and recent evidence suggests that effects on bone resorption are also mediated, at least in part, via osteoblastic cells.2,3 The considerable variations in antiresorptive potency between bisphosphonates may be attributable to different biochemical effects at the cellular level. The inhibitory effect is seen both for endogenous bone resorption and for resorption stimulated by agents such as parathyroid hormone, calcitriol, cytokines, and prostaglandins.
Inhibition of bone mineralisation
Bisphosphonates have a strong affinity for hydroxyapatite crystals and in fairly high doses inhibit calcification of bone in vivo by physicochemical mechanisms. The ability to inhibit mineralisation varies considerably between bisphosphonates and is not related to antiresorptive potency.
Pharmacokinetics
Bisphosphonates are not metabolised, and etidronate, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£23 / $37 / €30 (inc. VAT)
You can download a PDF version for your personal record.